Marvelon 28 Dosage/Direction for Use

How to take Desogestrel/Ethinylestradiol (Marvelon 28): Tablets must be taken in the order directed on the package every day at about the same time with some liquid as needed. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day placebo tablet interval, during which time a withdrawal bleed usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.
How to start taking Desogestrel/Ethinylestradiol (Marvelon 28): No preceding hormonal contraceptive use [in the past month]: Tablet-taking has to start on day 1 of the woman's natural cycle (i.e. the first day of patient's menstrual bleeding). Starting on days 2-5 is allowed, but during the first cycle a barrier method is recommended in addition for the first 7 days of tablet-taking.
Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, or transdermal patch): The woman should start with Desogestrel/Ethinylestradiol (Marvelon 28) preferably on the day after the last active tablet (the last tablet containing the active substances) of the previous COC, but at the latest on the day following the usual tablet-free or placebo tablet interval of the previous COC. In case a vaginal ring or transdermal patch has been used, the woman should start using Desogestrel/Ethinylestradiol (Marvelon 28) preferably on the day of removal, but at the latest when the next application would have been due.
If the woman has been using the previous method consistently and correctly and if it is reasonably certain that the patient is not pregnant, patient may also switch from the previous combined hormonal contraceptive on any day of the cycle.
The hormone-free interval of the previous method should never be extended beyond its recommended length.
Changing from a progestogen-only-method (minipill, injection, implant) or from a progestogen-releasing intrauterine system (IUS): The woman may switch any day from the minipill (from an implant or the IUS on the day of its removal, from an injectable when the next injection would be due), but should in all of these cases be advised to additionally use a barrier method for the first 7 days of tablet-taking.
Following first-trimester abortion: The woman may start immediately. When doing so, patient needs not take additional contraceptive measures.
Following delivery or second-trimester abortion: For breastfeeding women, see Use in Pregnancy & Lactation.
Women should be advised to start at day 21 to 28 after delivery or second-trimester abortion. When starting later, the woman should be advised to additionally use a barrier method for the first 7 days of tablet-taking. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman has to wait for the first menstrual period.
The increased risk of VTE during the postpartum period should be considered when restarting Desogestrel/Ethinylestradiol (Marvelon 28) (see Precautions).
Management of missed tablets: If the user is less than 12 hours late in taking any tablet, contraceptive protection is not reduced. The woman should take the tablet as soon as woman remembers and should take further tablets at the usual time.
If the patient is more than 12 hours late in taking any tablet, contraceptive protection may be reduced. The management of missed tablets can be guided by the following two basic rules: 1. tablet-taking must never be discontinued for longer than 7 days.
2. 7 days of uninterrupted tablet-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.
Accordingly the following advice can be given in daily practice: Week 1: The user should take the last missed tablet as soon as patient remembers, even if this means taking two tablets at the same time. The patient then continues to take tablets at the usual time. In addition, a barrier method such as a condom should be used for the next 7 days. If intercourse took place in the preceding 7 days, the possibility of a pregnancy should be considered. The more tablets are missed and the closer they are to the regular placebo tablet interval, the higher the risk of a pregnancy.
Week 2: The user should take the last missed tablet as soon as patient remembers, even if this means taking two tablets at the same time. The patient then continues to take tablets at the usual time. Provided that the woman has taken the tablets correctly in the 7 days preceding the first missed tablet, there is no need to use extra contraceptive precautions. However, if this is not the case, or if patient missed more than 1 tablet, the woman should be advised to use extra precautions for 7 days.
Week 3: The risk of reduced reliability is imminent because of the forthcoming placebo tablet interval. However, by adjusting the tablet-intake schedule, reduced contraceptive protection can still be prevented. By adhering to either of the following two options, there is therefore no need to use extra contraceptive precautions, provided that in the 7 days preceding the first missed tablet the woman has taken all tablets correctly. If this is not the case, the woman should be advised to follow the first of these two options and to use extra precautions for the next 7 days as well.
1. The user should take the last missed tablet as soon as patient remembers, even if this means taking two tablets at the same time. The patient then continues to take tablets at the usual time. The next pack must be started as soon as the current pack is finished, i.e., no gap should be left between packs. The user is unlikely to have a withdrawal bleed until the end of the second pack, but patient may experience spotting or breakthrough bleeding on tablet-taking days.
2. The woman may also be advised to discontinue tablet-taking from the current pack. Patient should then have a placebo tablet interval of up to 7 days, including the days the patient missed tablets, and subsequently continue with the next pack.
Week 4: Contraceptive protection is not reduced; the woman should take further tablets at the usual time.
If the woman missed tablets and subsequently has no withdrawal bleed in the first normal placebo tablet interval, the possibility of a pregnancy should be considered.
Advice in case of gastro-intestinal disturbances: In case of severe gastro-intestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken.
If vomiting occurs within 3-4 hours after tablet-taking, the advice concerning missed tablets, as given in Management of missed tablets, is applicable. If the woman does not want to change the normal tablet-taking schedule, patient has to take the extra tablet(s) needed from another pack.
How to shift periods or how to delay a period: To delay a period, the woman should continue with another pack of Desogestrel/Ethinylestradiol (Marvelon 28) without a placebo tablet interval. The extension can be carried on for as long as wished until the end of the second pack. During the extension the woman may experience breakthrough bleeding or spotting. Regular intake of Desogestrel/Ethinylestradiol (Marvelon 28) is then resumed after the usual 7-day placebo tablet interval.
To shift the period to another day of the week than the woman is used to with the current scheme, the patient can be advised to shorten the forthcoming placebo tablet interval by as many days as the patient likes. The shorter the interval, the higher the risk that the patient does not have a withdrawal bleed and will experience breakthrough bleeding and spotting during the second pack (just as when delaying a period).